IGI Laboratories Announces Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Roth Capital Upgrades IGI Laboratories (IG) to Buy; Sees 2016 at Break-Out Year
July 24, 2015 6:58 AM EDTRoth Capital upgraded IGI Laboratories (NYSE: IG) from Neutral to Buy with a price target of $11.00 (from $7.00), saying 2016 could be a break-out year.
Analyst Scott Henry commented, "The impetus for our upgrade is stabilization of the econazole nitrate franchise, a lower valuation, and... More
IGI Labs (IG) Tops Q2 EPS by 4c
July 23, 2015 4:25 PM EDTIGI Labs (NYSE: IG) reported Q2 EPS of ($0.04), $0.04 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $8.9 million versus the consensus estimate of $7.63 million.
IGI Labs reaffirmed FY2015 guidance.
IGI's President and Chief Executive Officer, Jason Grenfell-Gardner, stated, "We are pleased with our steady progress this quarter. On the regulatory front, we received the FDA's final approval for our diclofenac sodium 1.5%... More
